Ocular toxicity of intravitreal vidarabine solubilized in dimethyl sulfoxide.

Intravitreal injections of the antiviral drug vidarabine in doses of 10, 50, 100, and 200 micrograms dissolved in 100% dimethyl sulfoxide (DMSO) were administered to the eyes of 12 Dutch and New Zealand pigmented rabbits to determine ocular toxicity. The eyes were examined one week, one month, and two months after inoculation with slit-lamp biomicroscopy, indirect ophthalmoscopy, electroretinography, and histopathologic examination with light and electron microscopy. No permanent damage to ocular tissue was found at a vidarabine concentration of 100 micrograms/mL. The antiviral activity and the toxicity of the vidarabine dissolved in DMSO were tested in vitro on herpes simplex virus type 1-infected rabbit corneal fibroblast monolayers. Vidarabine dissolved in DMSO was found to possess in vitro antiviral activity against herpes simplex virus type 1. Our results suggest that the intravitreal administration of vidarabine dissolved in DMSO may be a safe and effective means of drug therapy.

[1]  T. Stelmack,et al.  Toxicity of intravitreal antiviral drugs. , 1984, Ophthalmic surgery.

[2]  M. Yoshizumi,et al.  Ocular Toxicity of Experimental Intravitreal DMSO , 1983 .

[3]  A. Lerner,et al.  Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis , 1981, Antimicrobial Agents and Chemotherapy.

[4]  T. Merigan,et al.  Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. , 1980, Annals of internal medicine.

[5]  H. Balfour,et al.  A trial of vidarabine for cytomegalovirus infection in renal transplant patients. , 1980, Archives of internal medicine.

[6]  Y. Tano,et al.  Inhibition of intraocular proliferations with intravitreal corticosteroids. , 1980, American journal of ophthalmology.

[7]  D. Pavan-Langston,et al.  Ocular and systemic antiviral activity of vidarabine. , 1977, Comprehensive therapy.

[8]  Lerner Am,et al.  Inhibitory and lethal concentrations of 9-beta-D-arabinofuranosyladenine and its hypoxanthine-derivative versus herpes simplex virus, type 1. , 1977 .

[9]  Baum Jl.  Antibotics administration in the treatment of bacterial endophthalmitis. I. Periocular injections. , 1977 .

[10]  A. Lerner,et al.  Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans. , 1976, The Journal of infectious diseases.

[11]  A. Julià,et al.  Toxicity of adenine arabinoside in humans. , 1976, The Journal of infectious diseases.

[12]  J. H. Elliott,et al.  Vidarabine therapy of complicated herpes simplex keratitis. , 1976, American journal of ophthalmology.

[13]  R. Buchanan,et al.  Effect of adenine arabinoside on cytomegalovirus infections. , 1974, The Journal of infectious diseases.

[14]  D. Pavan-Langston,et al.  Intraocular penetration of Ara A and idu-therapeutic implications in clinical herpetic uveitis. , 1973, Transactions - American Academy of Ophthalmology and Otolaryngology. American Academy of Ophthalmology and Otolaryngology.

[15]  L. Goodman,et al.  POTENTIAL ANTICANCER AGENTS.1 XL. SYNTHESIS OF THE β-ANOMER OF 9-(D-ARABINOFURANOSYL)-ADENINE , 1960 .